重组人生长激素治疗综合征型与非综合征型小于胎龄儿矮身材的疗效分析
回顾性分析59例接受重组人生长激素治疗的矮身材小于胎龄儿,比较综合征型与非综合征型的疗效及代谢参数。两组治疗12和24个月后身高标准差积分差值无显著差异,但非综合征型治疗12个月时胰岛素抵抗指数显著更高。结论认为两型疗效相当,但非综合征型需更频繁随访以关注胰岛素抵抗。
要点
- 综合征型与非综合征型SGA矮身材患儿rhGH治疗12和24个月后身高增长无显著差异。
- 非综合征型患儿治疗12个月时HOMA-IR显著高于综合征型。
- 非综合征型患儿身高增长在24个月内各时间点均持续显著,综合征型仅前12个月显著。
核心结论
- 综合征型与非综合征型矮身材的小于胎龄儿应用重组人生长激素疗效相当。
- 非综合征型患儿应用重组人生长激素治疗时更需要关注胰岛素抵抗程度,可能需要缩短随访间期。
研究设计与样本
- 回顾性分析2012年7月至2021年6月北京儿童医院内分泌遗传代谢科59例矮身材小于胎龄儿患儿的临床资料。
- 根据2019年矮身材共识分为综合征型27例与非综合征型32例,男37例、女22例,年龄(5.5±2.3)岁。
主要发现
- 治疗12个月后ΔHt-SDS两组差异无统计学意义(0.9±0.4比1.2±0.4,t=1.68,P=0.104)。
- 治疗24个月后ΔHt-SDS两组差异无统计学意义(1.4±0.7比1.9±0.5,t=1.52,P=0.151)。
- 治疗12个月时非综合征型HOMA-IR显著高于综合征型[2.29(1.43,2.99)比0.90(0.55,1.40),Z=-2.95,P=0.003]。
- 综合征型仅治疗6个月较治疗前、12个月较6个月Ht-SDS差异有统计学意义(Z=7.65、2.83,P<0.001、P=0.020)。
- 非综合征型治疗6个月较治疗前、12个月较6个月、18个月较12个月、24个月较18个月Ht-SDS差异均有统计学意义(Z=11.95、7.54、4.26、3.83,均P<0.001)。
临床怎么用
- 对综合征型与非综合征型SGA矮身材患儿均可考虑rhGH治疗,两者身高增长疗效相当。
- 非综合征型患儿rhGH治疗期间应更关注胰岛素抵抗程度,可能需要缩短随访间期。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To analyse the efficacy of recombinant human growth hormone (rhGH) treatment in children born small for gestational age (SGA) with syndormic and non-syndormic short stature. Methods: The clinical data of 59 children born SGA who were diagnosed as short stature and admitted to the Center of Endocrinology, Genetics and Metabolism, Beijing Children's Hospital from July 2012 to June 2021 were collected and analyzed. According to the 2019 consensus on short stature, they were divided into syndromic group and non-syndromic group. Before treatment and 6, 12, 18 and 24 months after treatment, height standard deviation score (Ht-SDS), difference of height standard deviation (∆Ht-SDS) and homeostasis model assessment-insulin resistance index (HOMA-IR) were compared between groups, while Ht-SDS and HOMA-IR were compared before and after treatment. Independent t test or Kruskal-Wallis test were used for comparison between the 2 groups, and paired t test or Mann-Whitney U test were used for the intra-group comparison. Results: Among the 59 cases, 37 were males and 22 females, aged (5.5±2.3) years. There was no significant difference in Ht-SDS after 12 months of treatment between 2 groups (0.9±0.4 vs. 1.2±0.4, t=1.68, P=0.104) or in height SDS after 24 months of treatment (1.4±0.7 vs. 1.9±0.5, t=1.52, P=0.151). After 12 months of treatment, the insulin resistance index of the non-syndromic group was significantly higher than that of the syndromic group (2.29 (1.43, 2.99) vs. 0.90 (0.55, 1.40), Z=-2.95, P=0.003). There were significant differences in Ht-SDS between 6 months and before treatment, 12 months and 6 months in syndromic type (Z=7.65, 2.83 P<0.001, P=0.020), but all were significant differences in non-syndromic type between 6 months and before treatment, 12 months and 6 months, 18 months and 12 months, 24 months and 18 months (Z=11.95, 7.54, 4.26, 3.83, all P<0.001). Conclusion: The efficacy of rhGH treatment in children born SGA is comparable between syndromic and non-syndromic short stature cases, but non-syndromic children treated with rhGH need more frequent follow-up due to the risk of insulin resistance. 目的: 比较重组人生长激素治疗综合征型和非综合征型矮身材的小于胎龄儿的效果及代谢参数变化。 方法: 回顾性分析2012年7月至2021年6月就诊于北京儿童医院内分泌遗传代谢科且应用重组人生长激素治疗的59例矮身材小于胎龄儿患儿的临床资料,根据2019年矮身材共识分为综合征型与非综合征型,在治疗前、治疗后6、12、18及24个月时,组间采用独立t检验或Kruskal-Wallis秩和检验,比较身高标准差积分(Ht-SDS)、身高标准差积分差值(∆Ht-SDS)及稳态模型-胰岛素抵抗指数(HOMA-IR);组内采用配对t检验或U检验,比较治疗前后Ht-SDS及HOMA-IR。 结果: 59例患儿中男37例、女22例,年龄(5.5±2.3)岁,综合征型27例、非综合征型32例。综合征型及非综合征型患儿在治疗12及24个月后ΔHt-SDS差异均无统计学意义(0.9±0.4比1.2±0.4,1.4±0.7比1.9±0.5,t=1.68、1.52,P=0.104、0.151);治疗12个月时非综合征型患儿的HOMA-IR较综合征型更高[2.29(1.43,2.99)比0.90(0.55,1.40),Z=-2.95,P=0.003];综合征型仅在治疗6个月时较治疗前、12个月时较6个月时Ht-SDS的差异有统计学意义(Z=7.65、2.83,P<0.001、P=0.020),非综合征型治疗6个月时较治疗前、12个月较6个月、18个月较12个月,24个月较18个月时Ht-SDS的差异均有统计学意义(Z=11.95、7.54、4.26、3.83,均P<0.001)。 结论: 综合征型与非综合征型矮身材的小于胎龄儿应用重组人生长激素疗效相当,但前者身高增长主要在治疗第1年;对于非综合征型患儿应用重组人生长激素治疗时更需要关注胰岛素抵抗程度,可能需要缩短随访间期。.
引用
- Cheng M, Cao BY, Liu M, et al. [Efficacy of recombinant human growth hormone treatment in children born small for gestational age with syndromic and non-syndromic short stature]. Zhonghua Er Ke Za Zhi. 2022. PMID: 36319157. doi:10.3760/cma.j.cn112140-20220324-00242
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。